Literature DB >> 2042651

Minimal change nephrotic syndrome in adults: response to corticosteroid therapy and frequency of relapse.

S Fujimoto1, Y Yamamoto, S Hisanaga, S Morita, T Eto, K Tanaka.   

Abstract

Rate of response to a corticosteroid and frequency of relapse were studied in 33 patients with adult-onset minimal change nephrotic syndrome (MCNS). Of these, 28 patients were treated with oral prednisolone (PSL) at 1 mg/kg/d for from 4 to 8 weeks depending on their response, followed by PSL, at gradually tapering doses for 1 year. Five severely nephrotic patients received 1 g of methylprednisolone intravenously (IV) for 3 days, followed by 40 mg/d oral PSL for 4 to 8 weeks and finally PSL in gradually reduced doses. Sixteen patients (48%) were free of proteinuria within 4 weeks, and 25 (76%) within 8 weeks. Two patients required cyclophosphamide for induction of remission. Age at presentation was not significantly correlated with response time to corticosteroid therapy. Thirty-two (97%) went into remission, and relapse occurred in 11 (34%) of these. As assessed by the life-table method, 84% of patients were still in remission at 6 months after induction of remission, 75% after 1 year, and 63% during the follow-up period (mean, 47.1 +/- 29.1 months; range, 6 to 123 months). Incidence of relapse was not correlated with remission induction time, ie, earlier (less than or equal to 4 weeks) or later (greater than 4 weeks), but was greater in younger (less than 30 years of age) patients than older (greater than or equal to 30 years) patients (P less than 0.03). At the last follow-up, 31 patients (94%) were in complete remission and had normal renal function.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2042651     DOI: 10.1016/s0272-6386(12)80353-2

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  12 in total

1.  The characteristics of relapse in adult-onset minimal-change nephrotic syndrome.

Authors:  Takashi Takei; Minako Koike; Koichi Suzuki; Satsuki Shirota; Mitsuyo Itabashi; Shigeru Ohtsubo; Hidekazu Sugiura; Keiko Suzuki; Chiari Kojima; Masaki Takahashi; Jun Ino; Tetsuya Ogawa; Keiko Uchida; Ken Tsuchiya; Wako Yumura; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2007-09-28       Impact factor: 2.801

2.  Successful treatment by mycophenolate mofetil in a patient with focal segmental glomerulosclerosis associated with posterior reversible encephalopathy syndrome.

Authors:  Masafumi Tenta; Haruhito Adam Uchida; Tomokazu Nunoue; Ryoko Umebayashi; Yuka Okuyama; Masashi Kitagawa; Yohei Maeshima; Hitoshi Sugiyama; Jun Wada
Journal:  CEN Case Rep       Date:  2014-12-30

3.  Age and prediction of remission and relapse of proteinuria and corticosteroid-related adverse events in adult-onset minimal-change disease: a retrospective cohort study.

Authors:  Maki Shinzawa; Ryohei Yamamoto; Yasuyuki Nagasawa; Susumu Oseto; Daisuke Mori; Kodo Tomida; Terumasa Hayashi; Masaaki Izumi; Megumu Fukunaga; Atsushi Yamauchi; Yoshiharu Tsubakihara; Hiromi Rakugi; Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2013-03-20       Impact factor: 2.801

4.  Adult-onset minimal change disease: the significance of histological chronic changes for clinical presentation and outcome.

Authors:  Gabriel Stefan; Ruxandra Busuioc; Simona Stancu; Madalina Hoinoiu; Adrian Zugravu; Nicoleta Petre; Gabriel Mircescu
Journal:  Clin Exp Nephrol       Date:  2020-10-22       Impact factor: 2.801

5.  Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort study.

Authors:  Maki Shinzawa; Ryohei Yamamoto; Yasuyuki Nagasawa; Susumu Oseto; Daisuke Mori; Kodo Tomida; Terumasa Hayashi; Masaaki Izumi; Megumu Fukunaga; Atsushi Yamauchi; Yoshiharu Tsubakihara; Yoshitaka Isaka
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

6.  Immunosuppressive treatment for idiopathic nephrotic syndrome with corticosteroids and cyclophosphamide: factors associated with a favourable outcome.

Authors:  M Pirisi; R Faedda; A Satta; E Bartoli
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

7.  Efficacy of Semiannual Single Fixed Low-Dose Rituximab Therapy in Steroid-Dependent Minimal Change Nephrotic Syndrome: A Case Series.

Authors:  Ryosuke Usui; Yohei Tsuchiya; Kosaku Nitta; Minako Koike
Journal:  Case Rep Nephrol Dial       Date:  2018-10-22

8.  Adult minimal-change disease: observational data from a UK centre on patient characteristics, therapies, and outcomes.

Authors:  Anthony Fenton; Stuart W Smith; Peter Hewins
Journal:  BMC Nephrol       Date:  2018-08-16       Impact factor: 2.388

9.  Corticosteroids vs. corticosteroids plus cycloporin A in adult minimal changes disease.

Authors:  Dimitrios S Goumenos; Pantelitsa Kalliakmani; Eirini Savvidaki; John G Vlachojannis
Journal:  BMC Res Notes       Date:  2009-07-22

10.  Idiopathic Nephrotic Syndrome: Characteristics and Identification of Prognostic Factors.

Authors:  Charlotte Dumas De La Roque; Mathilde Prezelin-Reydit; Agathe Vermorel; Sébastien Lepreux; Colette Deminière; Christian Combe; Claire Rigothier
Journal:  J Clin Med       Date:  2018-09-09       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.